Medicenna Therapeutics Joins Key Healthcare Event
TORONTO and HOUSTON — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a pioneering clinical-stage immunotherapy company, is excited to announce participation in a significant healthcare opportunity conference. This event focuses on the development of innovative Superkines targeted at combating cancer and addressing autoimmune diseases.
Details on the Healthcare Conference
Dr. Fahar Merchant, the esteemed President and CEO of Medicenna, is set to engage in discussions at the upcoming ROTH 4th Annual Healthcare Opportunities Conference. Taking place at the prestigious Metropolitan Club, this event promises enriching discourse from October 8-9.
Event Overview
This year’s conference format features 1-on-1 and small group meetings that allow institutional investors unparalleled interaction with executive management. It’s an excellent opportunity for guests to gain valuable insights into the innovations and developments shaping Medicenna’s efforts in the therapeutic landscape.
About ROTH
ROTH is a distinguished investment bank dedicated to fostering relationships and supporting growth companies. Their comprehensive service offerings include capital raising, equity research, macroeconomic analysis, and corporate access, all tailored to enhance investor engagement.
ROTH’s Commitment
Headquartered in Newport Beach, ROTH is a renowned employee-owned firm with a network of offices across the U.S., dedicated to cultivating partnerships that drive growth and innovation.
Medicenna’s Innovative Approaches
Medicenna Therapeutics is at the forefront of immunotherapy innovation. Their research primarily emphasizes the development of novel Superkines such as IL-2, IL-4, and IL-13, as well as first-of-their-kind Empowered Superkines. A highlight of their portfolio is MDNA11, a long-acting IL-2 Superkine designed to preferentially stimulate cancer-killing effector T cells while avoiding unwanted side effects associated with traditional IL-2 therapies.
The Advancements of Bizaxofusp
Medicenna has also pioneered bizaxofusp (formerly MDNA55), an IL-4 Empowered Superkine that has shown promise through five clinical trials, including a Phase 2b trial targeting recurrent glioblastoma (GBM), a notoriously aggressive form of brain cancer. Recognition of its potential has led to Fast Track and Orphan Drug designations from the FDA, underscoring its importance in modern therapeutic strategies.
Future Directions for Medicenna
In addition to their current initiatives, Medicenna is investing in early-stage BiSKITs™ and the T-MASK™ programs. These innovative therapies are being developed with the intent to target and activate immunologically “cold” tumors, which previously have been challenging to treat effectively. This commitment to overcoming current limitations in cancer treatment exemplifies Medicenna's dedication to advancing healthcare.
Stay Updated with Medicenna
For those eager to learn more about Medicenna’s groundbreaking work in immunotherapy, more information can be found on their official website. Follow them on social media platforms like Twitter and LinkedIn for real-time updates and insights.
Frequently Asked Questions
What is Medicenna Therapeutics known for?
Medicenna Therapeutics is renowned for its clinical-stage immunotherapy products focused on developing Superkines for cancer and autoimmune disease treatments.
Who will represent Medicenna at the conference?
Dr. Fahar Merchant, President and CEO of Medicenna, will participate and share insights during the ROTH Healthcare Opportunities Conference.
Where is the ROTH conference being held?
The conference will take place at the Metropolitan Club, located in New York City.
What are the main therapies Medicenna is developing?
Medicenna is developing novel Superkines such as MDNA11 and bizaxofusp, aimed at treating various cancers and improving immune responses.
How can I learn more about Medicenna’s work?
You can learn more by visiting their website or following them on social media for the latest updates on their research and clinical trials.
